Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants (vol 8, 167, 2023)

Summary: In this study, a recombinant adenovirus vaccine was developed for the Omicron variant of SARS-CoV-2. Intranasal vaccination was found to induce mucosal and systemic immune responses, effectively protecting against multiple Omicron subvariants. The vaccine also showed neutralizing effects against a range of other variants, indicating its potential as a transmission-blocking vaccine.